Abstract 244P
Background
To evaluate the practical significance of the effectiveness of the modified coloring solution “CIN-DIAG” in the diagnosis of pathological changes of the cervix.
Methods
The modified CIN-DIAG coloring solution is a sterile cotton swab on a plastic stick in a plastic tube, and the coloring solution is in the cap of the tube. Appearance of the coloring solution: a clear brown liquid; The volume of the coloring solution is 2 ml ± 5%; the pH of the coloring solution is in the range of 4 to 7 units. Mechanism of action: after applying the staining solution to the epithelial tissue, in the presence of atypical cells, folic acid, via the folate receptors on the surface of these cells, quickly enters the cytoplasm, is oxidized by the active oxygen present in the cell, and the tampon stains at different intensities. Normal cells have a low content of active oxygen, so there is little expression of folic acid receptors on the surface of the cells and the tampon does not stain after the reaction.
Results
The study included 20 (100%) patients, of which: with CIN I - 5 (25%), CIN II - 3 (15%), CIN III - 4 (20%), patients with cervical cancer - 5 (25 %), with cervical erosion - 2 (10%) and 1 (5%) women with a visually unchanged cervix. The age of women ranged from 29 to 64 years, the average age was 40 ± 0.7 years (p>0,5). In case CIN1, the tampon was colored dark green, with CIN2 it was blue-green, with CIN3 it was blue, and with cervical cancer, it was dark gray and black. The results obtained fully met the requirements of the regulatory document, the sensitivity of the coloring solution was 98%, the specificity was 95%.
Conclusions
Thus, the modified CIN-DIAG coloring solution has the advantages of economy, affordability, low technical requirements, safety and non-invasiveness, as a result of which it can be successfully applied in remote regions of the country.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session